The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
Official Title: A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas
Study ID: NCT05147558
Brief Summary: The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to find out whether biomarkers in the blood can predict the cancer's response to the study treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States
Name: Vicky Makker, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR